Neuome Peptides is a Peptide-based applied Technologies company Using Peptide-based Antigen Tests (PAT) to achieve lab-quality diagnostic results in substantially reduced time. Their motto of “Convergence of Science” is reflected in every product that they have built.

Neuome Peptides Pte Ltd has four divisions, namely the Nanotechnology, Biology, Biomedical Electronics and IT-IoT divisions. Peptides are unique molecules with high flexibility of use in different aspects of healthcare ranging from diagnostics and imaging to therapeutics. Their innovations are data-driven and backed by certified data from Clinical Trials executed in their in-house research labs in Singapore and India.

Their non-invasive COVID test kits include TruCov-Breath, TruCov-Saliva, and TruCov-Flow. They use a unique peptide-based testing approach and were a game changer in the way Covid testing was done by offering results in seconds and were precise enough as compared with RT-PCR.

Neuome Peptides is in the advanced stages of developing a point-of-care cardiac biomarker assay, that can give results within 3 to 5 minutes, using a finger prick sample to test not only for Troponins I and T but also Myoglobin, thus providing an enhanced diagnosis. Their technology for detecting these biomarkers uses a unique ability to bind at more than one binding site when conjugated with gold nanoparticles. Such highly sensitive assay platforms can enable early detection of biomarkers even at very low concentrations, without needing a laboratory. The test can be used at home, in ambulances, or in emergency rooms, where the results can be acted upon immediately.

Their current technologies research focuses on Tuberculosis, prostate cancer, Colorectal cancer, Dengue virus, Malaria virus, Chikungunya virus, D-Diamer for blood clotting, and Brain natriuretic Peptide.